Dr. Ned T. Rupp, M.D.
Allergy & Immunology (Allergy & Immunology Physician)
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
SC license 19514
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
| Service | Times | Patients |
|---|---|---|
| Injection, omalizumab, 5 mg | 3,345 | 14 |
| Professional service for preparation and provision of 1 or more antigens | 1,084 | 41 |
| Test for allergy using allergenic extract | 589 | 13 |
| Professional service for multiple injections of allergen | 474 | 82 |
| Established patient office or other outpatient visit, 30-39 minutes | 177 | 114 |
| Established patient office or other outpatient visit, 20-29 minutes | 172 | 118 |
| Test to measure expiratory airflow and volume | 154 | 88 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 142 | 19 |
| Professional service for single injection of allergen | 84 | 17 |
| Test to measure the level of nitric oxide gas | 57 | 48 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Montelukast Sodium Other prescribers in North Charleston, SC | 27 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in North Charleston, SC | 21 |
| Dupixent Syringe (dupilumab) Other prescribers in North Charleston, SC | 15 |
| Fluticasone Propionate Other prescribers in North Charleston, SC | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 8 payments worth $5,373 in total to this clinician.
| Regeneron Healthcare Solutions, Inc. | $5,346 |
|---|---|
| Pfizer Inc. | $27.04 |
| Compensation for services other than consulting (speaking, faculty) | $5,075 |
|---|---|
| Travel and Lodging | $157 |
| Food and Beverage | $142 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. Apr 22, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,374 |
| Regeneron Healthcare Solutions, Inc. Apr 15, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,646 |
| Regeneron Healthcare Solutions, Inc. Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,055 |
| Regeneron Healthcare Solutions, Inc. Feb 13, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to HILTON HEAD ISLAND, SC · in-kind | $78.39 |
| Regeneron Healthcare Solutions, Inc. Feb 13, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to HILTON HEAD ISLAND, SC · in-kind | $78.39 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $7,744 in research payments for these studies, mostly to the institutions running them.
- Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
Regeneron Pharmaceuticals, Inc. · Completed · NCT05590585
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.